A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, ...

The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their ...

A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer ...

The US company’s rabies candidate, RBI-4000, was able to elicit an immune response comparable to Bavarian Nordic’s RavAvert.

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

A cancer vaccine generated using the cells left over after tumour removal surgery could help to keep patients from ...

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

Fortress Biotech and its subsidiary Helocyte have announced the dosing of the first subject in a multi-centre Phase II trial ...

Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...